# A Study of DM002 in Patients With Advanced Solid Tumors

> **NCT06751329** · PHASE1 · RECRUITING · sponsor: **Xadcera Biopharmaceutical (Suzhou) Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Ovarian Neoplasms
- Prostatic Neoplasms
- Endometrial Neoplasms
- Colorectal Neoplasms
- Solid Carcinoma

## Interventions

- **DRUG:** DM002

## Key facts

- **NCT ID:** NCT06751329
- **Lead sponsor:** Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2027-10-08
- **Final completion:** 2028-04-18
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751329, "A Study of DM002 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06751329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*